TrialInternational journal of molecular sciences2022

0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial.

Gabriel Sosne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.